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Abstract
The TSH receptor (TSHR) is the critical target for antibody
production in Graves’disease (GD). Insulin-like growth factor
1 receptor (IGF1R) has been proposed as a second
autoantigen in complications of GD such as orbitopathy.
We attempted to induce orbital tissue remodeling in mice
undergoing immunizations with plasmids encoding TSHR
and IGF1R delivered by in vivo skeletal muscle electropora-
tion, a procedure known to give a sustained, long-term
antibody response. Female BALB/c mice were challenged
with TSHR A-subunit or IGF1Ra subunit plasmid by
injection and electroporation. Mice challenged with TSHR
A-subunit plasmid resulted in high frequency (75%) of
hyperthyroidism and thyroid-stimulating antibodies. But
strikingly, immunization with TSHR A-subunit plasmid
also elicited antibody to IGF1Ra subunit. Mice challenged in
the same manner with IGF1Ra subunit plasmid produced
strong antibody responses to IGF1R, but did not undergo any
changes in phenotype. Simultaneous challenge by double
antigen immunization with the two plasmids in distant
anatomical sites reduced the incidence of hyperthyroidism,
potentially as a consequence of antigenic competition.
Thyroid glands from the TSHR A-subunit plasmid-
challenged group were enlarged with patchy microscopic
inﬁltrates. Histological analysis of the orbital tissues demon-
strated moderate connective tissue ﬁbrosis and deposition of
Masson’s trichrome staining material. Our ﬁndings imply that
immunization with TSHR A-subunit plasmid leads to
generation of IGF1R antibodies, which together with
thyroid-stimulating antibodies may precipitate remodeling
of orbital tissue, raising our understanding of its close
association with GD.
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Introduction
Inﬂammation and remodeling of orbital tissues commonly
occur in the autoimmune thyroid disease, Graves’ disease
(GD). This process is referred to as thyroid eye disease,
thyroid-associated ophthalmopathy, or Graves’ orbitopathy
(GO) (Perros & Krassas 2009, Bahn 2010, Naik et al. 2010).
In GD, thyroid-stimulating antibodies (TSAbs) directed
against the TSH receptor (TSHR) activate the thyroid
gland, leading to excessive production of thyroid hormone
and thyrotoxicosis (Rees Smith et al. 1988). TSAbs may also
target TSHR expressed in extra-thyroidal tissues (Bell et al.
2000, Zhang et al. 2009). The characteristic tissue remodeling
in GO may be associated with enhanced adipogenesis and
deposition of glycosaminoglycans. It is currently believed that
these changes culminate in protrusion of the eyes (Bell et al.
2000, Zhang et al. 2009, Naik et al. 2010). The pathogenic
role of TSHR as a target antigen is well established in GD.
However, in GO, the extra-ocular muscles do not express
TSHR (Paschke et al. 1993), but a number of other eye
muscle antigens have been characterized with serum
antibodies from patients with GO (Gopinath et al. 2006). In
addition, insulin-like growth factor receptor 1 (IGF1R) has
been recognized as a relevant antigen in the pathogenesis of
GO, perhaps serving as a second autoantigen (Weightman
et al. 1993, Pritchard et al. 2003, Drexhage 2006). Resident
ﬁbroblasts and adipose tissue express functional TSHR and
IGF1R (Bell et al. 2000, Zhang et al. 2009) and represent
the key participants in orbital tissue remodeling in GO
(Smith 2003), Recently, bone marrow-derived CD34
C
ﬁbrocytes have been detected among the ﬁbroblasts inhabit-
ing the orbit in GO, which express both receptors (Douglas
et al. 2010, Kahaly 2010). Fibrocytes possess unique properties
that render them well suited for participation in the
pathological changes occurring in GO. Moreover, the
recent ﬁnding that TSHR and IGF1R are complexed in
thyrocytes and orbital ﬁbroblasts suggests a mechanism to
allow cross talk in signaling, which may provide additional,
but to date undermined, roles in the pathogenesis of GO
(Tsui et al. 2008).
GD occurs spontaneously in human beings but does not
appear to do so in any other species (Dagdelen et al. 2009).
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attempted by different procedures, including immunization
with TSHR fusion proteins puriﬁed from Escherichia coli
(E. coli) or transfer of cells expressing TSHR and major
histocompatibility complex( M H C )c l a s sI Ia n t i g e n s
(Costagliola et al.1 9 9 6 , Shimojo et al.1 9 9 6 ), but the most
reproducible models rely on genetic immunizations requiring
in vivo expression of TSHR (reviewed in Dagdelen et al.
(2009)).Inattempts to developGO inmice, Manyetal.( 1 9 9 9 )
reported amodelbasedontransferofTSHR-primedsplenicT
cells from mice immunized with TSHR fusion proteins to
naı ¨ve syngeneic animals, which showed remarkable orbital
changes manifest in BALB/c mice. Orbital pathology was
studied in ﬁxed sections and by immunohistochemistry in
frozensectionsusingleukocyte-speciﬁcantibodies.Theorbital
tissue showed dissociation of orbital muscle bundles by edema,
accompanied by accumulation of glycosaminoglycans and
adiposetissue togetherwithaninﬂammatoryinﬁltrateofTand
B cells and macrophages (Many et al. 1999). In a separate study
from the same group, but using genetic immunization to
induce hyperthyroidism in outbred mice, scattered mast cells
werealsoreportedintheorbitalmuscletissues(Costagliolaetal.
2000). Importantly, the reportedﬁndings have been difﬁcult to
substantiate (Baker et al. 2005). In another study, accumulation
of mast cells in orbital tissue was also reported after genetic
immunization of outbred mice with TSHR and G2s cDNA
(Yamada et al. 2002).
In studies using adenovirus encoding TSHR A-subunit
(amino acids 22–289; Chen et al. 2003), we were unable to
provoke either thyroiditis or orbital inﬂammation, but that
strategy induced very strong thyroid-stimulating antibodies
(TSAbs) associated with a high incidence of hyperthyroidism
(Gilbert et al. 2006). Recently, improvements in the delivery
of plasmid encoding TSHR have relied on plasmid injection
combined with muscle electroporation in vivo (Kaneda et al.
2007). The electroporation technique results in enhanced
transfection efﬁciency, induces a strong antibody response to
TSHR, and results in frequent hyperthyroidism. Importantly,
this model generates long lasting immunity (Kaneda et al.
2007), which may be critical for the development of tissue
pathology. We now report that injection of plasmids encoding
human TSHR A-subunit combined with electroporation
results in hyperthyroidism, generation of TSAbs, appearance
of antibodies to IGF1R, microscopic thyroid inﬁltrates, and
moderate orbital ﬁbrosis.
Recently, Eckstein and colleagues have reported the
trafﬁcking of leukocytes into orbital tissue in C57/BL6
mice following immunization with TSHR A-subunit
encoding adenovirus or TSHR plasmid following depletion
of regulatory T cells (Johnson et al. 2010, Ziler et al. 2010).
The orbital inﬂammation data in immune C57/BL6 mice,
together with our ﬁndings of orbital ﬁbrosis in immune
BALB/c mice, suggest that orbital phenotypic alterations
characteristic of human GD can be induced in inbred mice
undergoing experimental hyperthyroidism, which will
facilitate our understanding of pathogenesis of GO.
Materials and Methods
Animals
BALB/c female mice (age 8–10 weeks) were purchased from
Harlan(Loughborough,UK)Ltd.Animalswerehousedunder
conventional conditions in cageswith ﬁlter top lids, with food
made available ad libitum. All animal experiments were
conducted according to UK Home Ofﬁce and King’s College
London regulations under full veterinary welfare care.
Cloning and preparation of plasmid DNA
Expression plasmids included i) pTriEx-1.1 Neo, a multi-
system expression plasmid (Novagen, Leicestershire, UK) and
ii) pCAGGS, a high-efﬁciency mammalian expression vector
(Niwa et al. 1991) (gift from Professor D J Wells, Imperial
College London). Human TSHR A-subunit (amino acid
residues 22–289) and human IGF1Ra subunit (741 amino
acids) were ampliﬁed for cloning. TSHR A-subunit cDNA
region was cloned into BamHI and NotI restriction sites in
pTriEx-1.1 Neo by ampliﬁcation from pcDNA3.1-human
TSHR plasmid (Rao et al. 2003) using forward primer
50-CGCGGATCCATGAGGCGATTTCGGAGG-30 and
reverse primer 50-ATAAGAA TGCGGCCGCTTACT-
GATTCTTAAAAGCACAGC-30 and KOD HiFi DNA
polymerase (Novagen) and cloned into pGEM-Teasy vector.
The cDNA was excised and subcloned into BamHI and
NotI-digested pTriEx-1.1 NeopTriEx-1.1 Neo vector.
Similarly, TSHR A-subunit cDNA region was cloned into
EcoRI restriction sites of pCAGGS vector by ampliﬁcation
from human TSHR/pcDNA3.1 plasmid using forward
primer 50-CCGGAATTCATGAGGCGATTTCGGAGG-30
and reverse primer 50-CCGGAATTCTTACTGATTCT-
TAAAAGCACAGC-30 and cloned into pGEM-Teasy vector.
The cDNA was excised and subcloned into EcoRI-digested
pCAGGS vector and orientation determined. The plasmids,
termed pTriEx-1.1 Neo–TSHR A-subunit and pCAGGS–
TSHR A-subunit, were fully sequenced in both strands.
IGF1Ra subunit cDNA was cloned from human orbital
ﬁbroblasts (Tsui et al. 2008). Brieﬂy, mRNA was reverse
transcribed into cDNA using an Omniscript RT Kit
(Qiagen). For PCR, forward primer 50-GAATGAAGTC-
TGGCTCCGGAGG-30 and reverse 50-CTCTCCGCTT-
CCT-TTCAGGTC-30 were used to generate a 2.2 kb PCR
fragment, which was then tibialis anterior (TA) cloned into
pCR2.1 vector (Invitrogen) and further subcloned in-frame
into a pEGFP-N1 vector (BD Biosciences, Oxford, UK) and
termed pEGFP–IGF1Ra–GFP. For generating IGF1Ra
subunit (741 amino acids) for cloning in pTriEx-1.1
NeopTriEx-1.1 Neo, the region of 2223 bp (including the
stop codon) was ampliﬁed from pEGFP–IGF1Ra–GFP with
KOD HiFi DNA polymerase, forward primer with BamHI
site: 50-CGCGGATCCATGAAGTCTGGCTCCGG-30
and reverse primer with NotI site: 50-ATAAGAA-
TGCGGCCGCTTATCTCCGCTTCCTTT CAGG-30,
S-X ZHAO and others . Graves’ orbitopathy after immunization with TSHR 370
Journal of Endocrinology (2011) 210, 369–377 www.endocrinology-journals.orgthen TA cloned into pGEM-T easy followed by subcloning
into pTriEx-1.1 NeopTriEx-1.1 Neo vector (Novagen) with
BamHI and NotI restriction sites. For cloning into EcoRI
restriction site in pCAGGS vector, the 2223 bp region was
ampliﬁed from pEGFP–IGF1Ra–GFP with KOD HiFi
DNA polymerase: forward primer 50-CCGGAATTCATG-
AAGTCTGGCTCCGG-30 and reverse primer 50-CC-
GGAATTCTT ATCTCCGCTTCCTTTCAGG-30 and
then TA cloned into pGEM-T easy followed by subcloning
into EcoRI-digested pCAGGS vector. The plasmids, termed
pTriEx-1.1 Neo–IGF1Ra and pCAGGS–IGF1Ra plasmid,
were fully sequenced in both strands to verify the ampliﬁed
sequence.
pTriEx-1.1 Neo b-gal (Novagen) and pCAGGS b-gal
were obtained from Dr D J Wells. All plasmids were grown in
E. coli XL-1 Blue cells in LB medium in 2.5 l cultures and
puriﬁed using the QIAﬁlter Plasmid Giga Kit (Qiagen).
Puriﬁed plasmid concentrations were measured using a
Nanodrop spectrophotometer, resuspended at 1 mg/ml in
sterile water, and stored at K80 8C. Single plasmid
preparations were used for the entire set of injections for
the group of animals.
I.m. injection and in vivo electroporation of plasmid DNA
For immunization, the parameters for electroporation were
selected as described (McMahon et al. 2001). The shaved TA
muscle of each hind leg of anesthetized mice was injected
with 25 ml plasmid (1 mg/ml in saline). Needles were aimed
caudal into the muscle. Injections were followed immediately
by electroporation with an ECM 830 system (BTX Harvard
Apparatus, Holliston, MA, USA) with 7 mm caliper
electrodes at 200 V/cm. This current was applied in ten
20 ms square wave pulses at 1 Hz and resulted in marked
muscle twitching. The biceps femoris (thigh) muscle of both
hind legs was injected in another group of animals. This site
could accommodate 50 ml plasmid injection (1 mg/ml in
saline) followed immediately by electroporation. Animals
recovered from anesthesia and were monitored for signs of
distress. They were treated four times at 3-week intervals
(Kaneda et al. 2007), bled by saphenous vein puncture at the
times indicated, and/or killed. Serum samples were stored at
K80 8C until assayed for TSAbs. Terminal samples were also
analyzed for TSH-binding inhibiting antibody (TBI) and
total serum thyroxine (T4).
Measurement of serum antibodies and thyroid function tests
Anti-TSHR antibodies TBI activity was measured in
serum samples following killing. Serum (100 ml) was analyzed
with TRAK II DYNO test human kits (ThermoScientiﬁc
Biomarkers, Henningsdorf, Germany) according to the
manufacturer’s instructions. Results are expressed as percen-
tage of inhibition of radiolabeled TSH binding (Rao et al.
2003, Gilbert et al. 2006). TSAbs were measured using 3 ml
serum in a bioassay in JP09 cells stably transfected with human
TSHR. Samples were diluted in NaCl-free isotonic Hank’s
balanced salt solution containing 0.5 mM isobutyl-1-methyl-
xanthine, sucrose, and HEPES, as described (Gilbert et al.
2006). cAMP was measured by RIA in a commercial kit; total
T4 was determined by RIA (ThermoScientiﬁc Biomarkers)
and basal values determined from four normal BALB/c mice
(Gilbert et al. 2006).
Anti-IGF1Ra Abs were measured in a coupled in vitro
transcription and translation system (TnT) radioligand-binding
assay (Tree et al. 2000, Bonifacio et al. 2010). Brieﬂy, IGF1Ra
subunit cDNA (2223 bp) was excised with BamHI/NotI
digestion from pGEM-T easy vector and cloned into pSP64
Poly(A)vector(Promega).ThisvectorcontainsanSP6promoter
to yield sense strand mRNA in the presence of SP6 RNA
polymerase and ribonucleotide triphosphates. In the coupled
TnT system, IGF1Ra s u b u n i ti sp r o d u c e da sar a d i o a c t i v e
35S-methionine-labeled nascent protein. The quality of
35S-radioactivity incorporated into the translated protein was
determined by precipitation with 10% trichloroacetic acid and
liquidscintillationcounting.Anti-IGF1Rantibodywasdetected
by overnight incubation of 5 ml mouse serum with aliquots of
35S-IGF1Ra-translated protein (20 000 c.p.m.) overnight at
4 8C in immunoprecipitation buffer (10 mM HEPES, 150 mM
NaCl, 20 mM methionine, 0.5m g / m lB S A ,a n d0 .5% Triton
X-100, pH 7.4). This was layered on protein G-Sepharose,
washed extensively by vacuum ﬁltration, and radioactivity was
counted. Rabbit anti-human IGF1R peptide antiserum N20
(N-terminus peptide, sc712) and antiserum C-20 (C-terminus
peptide, sc-713; Santa Cruz, Santa Cruz, CA, USA) served as
positive and negative controls respectively.
Histology
Thyroid–trachea preparations were ﬁxed in 10% buffered
formalin, embedded in parafﬁn, and sectioned for hematoxylin
and eosin (H&E) staining. To ensure that micro-inﬁltrates are
not missed, the entire two lobes of the thyroid gland were
sectioned serially at 4 mm, with the next ten serial step sections
discarded,followedbyretaininganother setofserialsectionuntil
theentireth yr oidglandhadbeensectioned(Kong2007).Mouse
extra-ocular muscles were accessed by transcranial dissection.
The entire orbital bony tissue comprising the orbital bones with
the eyeball, extraocular muscles, and the optic nerve was
carefully separated from the mouse and ﬁxed in buffered 10%
formalin. After 24 h, the orbital bony tissue was placed in 10%
decalciﬁcation solution for 7 days with one change of the
solution.Thereafter,theorbitaltissuewasembeddedinthesame
orientation in parafﬁn block, serial and step sections as described
above were performed starting from the lateral side (optic nerve
side). In contrast to the sectioning of the entire thyroid gland,
due to the ‘larger’size orbital tissue, it was not possible to section
t h ee n t i r el a t e r a ls i d eo ft h eo r b i t .T w os e r i a ls e c t i o n sw e r e
collectedafterevery ten-stepsections andsubjected separately to
H&E or Masson’s trichrome staining. For the orbit, at least three
toﬁvesections(afterten-stepsectionsdiscarded)wereexamined.
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Anti-IGF1Ra Absweredeemedpositive if titerswereO2 S.D.
above the mean of control mice immunized with pTriEx-1.1
Neo-b-gal plasmid. TSAbs levels were expressed as the fold
change compared to control sera in each experiment.
Results
Assessment of immunogenicity of different plasmids
We ﬁrst evaluated the immunogenicity of the two plasmids,
pTriEx-1.1 Neo or pCAGGS. BALB/c mice were injected
with pTriEx-1.1 Neo or pCAGGS plasmids containing
TSHR A-subunit or IGF1Ra subunit cDNA. This was
followed immediately by electroporation into both TA
muscles. Animals challenged with pTriEx-1.1 Neo–TSHR
A-subunit exhibited a robust generation of TSAbs following
the fourth injection in four of seven mice (Fig. 1). Antibody
levels peaked in individual mice at different times (Fig. 1). At
killing (10 weeks after the last injection), TSAbs could be
detected in two animals while one was hyperthyroid (Table 1,
mouse #4 and 5). Interestingly, TBI activity remained at a
high level in all animals (Table 1). We also tested immune
serum from this group of mice for antibody against IGF1Ra
subunit. Surprisingly, two mice were signiﬁcantly positive for
anti-IGF1Ra subunit antibodies (Table 1, #2 and 5). Thus,
the results indicate that TSAbs induced with pTriEx-1.1
Neo–TSHR A-subunit immunization and electroporation
group persist for at least 10 weeks after the last injection
(Fig. 1). Importantly, immunization with pTriEx-1.1
Neo–TSHR A-subunit can result in the generation of
antibodies to IGF1Ra subunit.
We next tested the efﬁcacy of the pCAGGS–TSHR
A-subunit plasmid by immunization combined with electro-
poration. TBI activity was strongly positive in serum (10
weeks after the fourth injection) in all animals in this group
(nZ8 mice), but remarkably all animals were negative for
TSAbs and none were hyperthyroid. In addition, all
pCAGGS–TSHR A-subunit challenge group animals were
negative for antibody to IGF1Ra (not shown). Thus, our
ﬁndings demonstrate the superiority of pTriEx-1.1
Neo–TSHR A-subunit in inducing TSAbs and experimental
hyperthyroidism. Moreover, immunization with pTriEx-1.1
Neo–TSHR A-subunit can also elicit production of
antibodies to IGF1Ra subunit.
Animals challenged with pTriEx-1.1 Neo–IGF1Ra
immunization combined with electroporation resulted in
detectable anti-IGF1Ra antibodies in all animals (Table 1).
We also tested the sera from this group for antibodies to
TSHR and found that they were uniformly undetectable.
Moreover, no animals developed hyperthyroidism. Immu-
nization with the different plasmid, pCAGGS–IGF1Ra,g a v e
comparable results (data not shown). All animals immunized
with the IGF1Ra plasmids appeared healthy.
Challenge with pTriEx-1.1 Neo plasmid constructs
Preliminary analysis of the results from plasmid injections
combined with electroporation indicated that pTriEx-1.1
Neo–TSHR A-subunit is effective in inducing TSAbs and
hyperthyroidism, as well as induction of antibodies to
IGF1Ra subunit. Therefore, this combination immunization
strategy using pTriEx-1.1Neo plasmids was used sub-
sequently. To increase transfected muscle volume, injections
were performed in biceps femoris (thigh) muscle combined
with electroporation. Groups of micewerechallenged in both
legs with either pTriEx-1.1 Neo–TSHR A-subunit or
pTriEx-1.1 Neo–IGF1Ra alone. In addition, another
group of animals received double plasmid combination by
immunization in different anatomical sites, by simultaneous
injection of pTriEx-1.1 Neo–TSHR A-subunit in one leg
and pTriEx-1.1 Neo–IGF1Ra in the other. These animals
were killed 6 weeks after the last (fourth) injection and serum
antibodies and tissue pathology were investigated. Control
serum from pTriEx-1.1 Neo-b-gal plasmid-immunized
animals (Table 1) was used in the analysis.
The results are summarized as follows (Table 2): TSAbs
were detected in 5/12 animals challenged with pTriEx-1.1
Neo–TSHR A-subunit alone with a high incidence of
hyperthyroidism (8/12 mice). Strikingly, anti-IGF1Ra
subunit was also detected in 3/12 animals (Table 2). In
contrast, all animals challenged with IGF1Ra alone develop
high-titer antibodies to IGF1Ra, but anti-TSHR could not
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Figure 1 Time course of TSAbs in mice immunized with pTriEx-1.1
Neo–TSHR A-subunit combined with electroporation. The abscissa
indicates blood sample collected 1 week after the injections and
continued every 3 weeks for another 10 weeks after the last
injection (see inset). The TSAbs on the ordinate are shown as fold
change over the response obtained with normal serum from six
mice, tested individually in the assay (different symbols indicate
each individual mouse). The inset shows the immunization proﬁle,
where plasmid injections were conducted four times (indicated by
small arrows) every 3 weeks apart, together with the timing of the
blood sample collection (large arrows).
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oidism. Challenge with double plasmid immunization in
different anatomical sites resulted in fewer hyperthyroid mice
(2/12 animals) compared with pTriEx-1.1 Neo–TSHR
A-subunit alone, which may be related to antigenic
competition (Hunt et al. 2001; Table 2).
Assessment of pathology in the thyroid and orbital tissue
Thyroid glands from pTriEx-1.1 Neo–TSHR A-subunit-
challenged mice were enlarged when compared to those
from animals immunized with pTriEx-1.1 Neo–IGF1a
alone. We then assessed the histopathology of all the thyroid
glands in the three groups of immune animals (Table 2). In
the group immunized with pTriEx-1.1 Neo–TSHR
A-subunit alone, 5/12 thyroids exhibited pathological
changes (Table 2, animals #1, 2, 4, 5, and 11), characterized
by micro-inﬁltrates (Fig. 2a). Three of the 12 thyroids
from those animals immunized in different anatomical sites
with pTriEx-1.1 Neo–TSHR A-subunit and pTriEx-1.1
Neo–IGF1Ra showed these changes (Table 2, animals #27,
28 and 31). In those animals exhibiting thyroid abnormal-
ities, examination of orbital tissue revealed ﬁbrosis in the
muscle tissue following H&E staining (Fig. 2b), together
with material staining with Masson’s trichrome (Fig. 2c).
Inspection of orbital tissue from control mice revealed no
abnormalities (Fig. 2d and e). Orbital tissue from an immune
animal, the thyroid of which was normal was also
unremarkable (Table 2, animal #12). Thyroid glands from
all animals in the group challenged with IGF1Ra plasmid
alone were normal, as was the orbital tissue (Table 2, animals
#17 and 21).
Table 1 Antibody status of individual mice at 10 weeks after last immunization with pTriEx-1.1 Neo–TSH receptor (TSHR) A-subunit or
pTriEx-1.1 Neo–IGF1Ra subunit or pTriEx-1.1 Neo-b-gal plasmid in tibialis anterior muscle combined with electroporation. The serum from
pTriEx-1.1 Neo-b-gal immunized mice were tested in duplicate wells and gave values of: mouse #16–529 and 682 c.p.m. (average
606 c.p.m.); mouse #17–535 and 659 c.p.m. (average 597 c.p.m.); mouse #18–667 and 611 c.p.m. (average 639 c.p.m.); mouse #19–788
and 1346 c.p.m. (average 1067 c.p.m.); mouse #20–848 and 880 c.p.m. (average 864 c.p.m.); mouse #21–844 and 1344 c.p.m. (average
1089 c.p.m.). MeanCS.D.Z1269 c.p.m. Values scoring higher than 1269 c.p.m., scored signiﬁcantly positive. Values highlighted in bold,
signiﬁcantly positive (meanC2 S.D.)
Mouse number
Immunogen plasmid
pTriEx-1.1 Neo
Anti-TSHR
inhibition (%)
a
TSAbs Fold
increase
b
Serum total
T4 (nmol/l)
c
Anti-IGF1Ra
(c.p.m.)
d
1 TSHR A-sub 85 0.6 57 1052
2 TSHR A-sub 88 0.55 8 1308
3 TSHR A-sub 87 0.6 83 1117
4 TSHR A-sub O90 4.5 132 1047
5 TSHR A-sub O90 2.4 67 1326
6 TSHR A-sub 79 0.7 47 1107
7 TSHR A-sub 81 1.3 28 930
8 IGF1Ra sub 3 0.55 0 1924
9 IGF1Ra sub 5 0.76 4 1456
10 IGF1Ra sub 7 0.74 4 1321
11 IGF1Ra sub 9 0.65 9 1420
12 IGF1Ra sub 6 0.74 7 1245
13 IGF1Ra sub 5 0.84 8 2079
14 IGF1Ra sub 3 1.13 5 1770
15 IGF1Ra sub 6 1.96 4 3009
16 b-Gal ND – 62 606
17 b-Gal ND – 81 597
18 b-Gal ND – 72 639
19 b-Gal ND – 58 1067
20 b-Gal ND – 72 864
21 b-Gal ND – 69 1089
Controls IGF1R assay
Positive Serum N20 (sc-712) – – – 11328
Negative Serum C20 (sc-713) – – – 694
ND, not determined.
aPercentage of inhibition of
125I-TSH binding in radioreceptor TRAK assay (ThermoScientiﬁc Biomarkers).
bThyroid-stimulating antibody (TSAb) assay in JP09 cells. Fold-increase over serum from pTriEx-1.1 Neo-b-gal immunized mice – all serum samples were
measured in duplicate wells, the average cAMP values for serum from the six b-gal plasmid immunized mice were 0.65, 0.98, 0.84, 0.58, 0.77, and
0.57 pmols/ml. With a mean of 0.73 pmol/ml, any test serum giving values higher than three fold mean value (2.19 pmols/ml) were considered positive. In the
assay, stimulation with suboptimal dose of bTSH (0.8 U/ml) and a thyroid-stimulating IgG mAb (KSAb1, 10 mg/ml) gave 27 and 27.5 pmols/ml cAMP
respectively.
cTotal T4: pTriEx-1.1 Neo-b-gal mice, MeanCS.D.Z85.9. Higher values scored signiﬁcantly positive.
dAnti-IGF1Ra samples, mean of duplicates (c.p.m.). The positive and negative control rabbit anti-IGF1R peptide antiserum is indicated. The c.p.m. of individual
triplicate wells for serum N20 (25 mg) were 10128, 14403, and 9454 c.p.m. (average 11 328 c.p.m.); for serum C20 (25 mg) were 595, 641 and 847 c.p.m.
(average 694 c.p.m.).
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From the observations made in the two studies presented
here, several novel ﬁndings emerge. We demonstrate
alterations in orbital tissues from BALB/c mice immunized
with pTriEx-1.1 Neo–TSHR A-subunit using i.m. injection
combined with electroporation. Unexpectedly, immuniz-
ation with pTriEx-1.1 Neo–TSHR A-subunit provokes the
production of antibodies speciﬁc for IGF1Ra subunit. In
addition to thyroid inﬂammation, our model shows orbital
changes. The lymphocyte inﬁltration in thyroid appeared as
small microinﬁltrates (Kong 2007) with patchy distribution.
Orbital tissue exhibited tissue remodeling and ﬁbrosis, which
stained positively with Masson’s trichrome. These changes,
suggesting accumulation of collagen and glycosaminoglycan,
were absent in control orbital tissue. In contrast, immuniz-
a t i o nw i t hI G F 1 R a plasmid efﬁciently induced anti-
IGF1Ra antibodies but was insufﬁcient to promote any
tissue pathology. Only animals with thyroid inﬁltrate appear
to exhibit orbital pathology. These exhibit partial ﬁdelity
with those found in human GO. We could not identify
cellular inﬁltrates in the orbits.
The current studies build on and reﬁne the ﬁndings of
Kaneda et al. (2007), who ﬁrst reported the combined plasmid
injection and electroporation approach to promoting experi-
mental GD. That report achieved efﬁcient induction of TSAbs
and hyperthyroidism, although lymphocyte inﬁltration of the
thyroid was absent and orbital tissues were not examined
(Kaneda et al.2 0 0 7 ). Explanation for the differences between
this study (Kaneda et al.2 0 0 7 ) and the results reported herein
remains incomplete, and several possibilities exist. Thyroid
enlargement was observed in some animals in both studies but
lymphocyte inﬁltrates were scant, suggesting the need for
sectioning entire thyroid glands (Kong 2007). The presence of
thyroid inﬂammation in our study might relate to the different
plasmidsused (Kaneda etal.2 0 0 7 ).In contrastto hyperthyroid-
ismandTSAbsfollowingimmunizationwithpTriEx-1.1Neo–
TSHR A-subunit, neither was found using pCAGGS–TSHR
A-subunit. This ﬁnding implies that each plasmid could
contribute differentially to the immune responses directed
against TSHR A-subunit, a ﬁnding also reported (Kaneda et al.
2007). In addition, the choice of electrodes used for
electroporation can strongly inﬂuence transfection efﬁciency
(Huntetal.2001,Cemazaretal.2006).Calliperplateelectrodes,
such as those used here, provide a more uniform electrical ﬁeld
over a wider area of the muscle compared to needle electrodes
(Kaneda et al.2 0 0 7 ), which in turn could inﬂuence immune
responses (Cemazar et al.2 0 0 6 , Wells et al.2 0 0 8 ).
(a) (b)
(d) (e)
100 µm 100 µm
100 µm
(c)
Figure 2 Histological analysis of the orbital and thyroid tissue to show pathology of the organs after challenge with pTriEx-1.1
Neo–TSHR A-subunit alone. (a) Hematoxylin and eosin (H&E) staining of thyroid gland from mouse number 2 (Table 2) to show
mononuclear cell microinﬁltrate next to a blood vessel (arrowed). (b) Orbital section from the same mouse, H&E staining to show
extensive ﬁbrosis in the muscle tissue and (c) Serial section from (b) after Masson’s trichrome staining to show deposition of collagen and
glycosaminoglycans (arrowed). (d) Orbital section of normal orbit, H&E staining and (e) Serial section from (d) after Masson’s trichrome
staining. Although (b and c) and (d and e) are serial sections from respective wax blocks, different staining procedures result in different
contractions of the section, hence do not align exactly. Magniﬁcation (a) !100; (b and c) !200; (d and e) !100. Full colour version of
this ﬁgure available via http://dx.doi.org/10.1530/JOE-11-0162.
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phenotype in our new model could result from the
peculiarities of the microbial environment. Our animals
were housed in conventional clean rooms (with the full range
of commensal bacteria and normal gut microﬂora), rather
than the speciﬁc pathogen-free conditions used in some
studies (Kaneda et al. 2007). In related studies from this
laboratory, when immunization with adenovirus expressing
TSHR A-subunit was utilized, the incidence of hyperthyr-
oidism occurring in animals housed in clean rooms (Gilbert et
al. 2006) was congruent with the ﬁndings of animals housed
in pathogen-free conditions (Chen et al. 2003, Mizutori et al.
2006). Indeed, these earlier studies using the adenovirus
model uniformly failed to exhibit thyroiditis, suggesting that
clean versus pathogen-free housing conditions do not fully
account for our divergent observations.
Several authors have suggested a potential role for
antibodies against IGF1R playing a pathogenic role in GO
(Weightman et al. 1993, Pritchard et al. 2003, Smith 2003,
Drexhage 2006). While such a scenario clearly explains the
association of the condition with GD, it has proven
challenging to study the IGF1R antibodies in GO (Pritchard
et al. 2003, Naik et al. 2010). Indeed, it is worth emphasizing
that despite their potential intrinsic role in orbital pathology
(Smith 2003, Drexhage 2006), the antigen(s)-stimulating
pathogenic B cell clones to generate anti-IGF1R antibody
remain incompletely deﬁned (Smith 2003, Naik et al. 2010).
In this study, we observed the presence of antibodies to
IGF1Ra subunit following immunization with TSHR
A-subunit. One explanation for the anti-IGF1Ra antibodies
following immunization with TSHR A-subunit may be
related to the fact that TSHR and IGF1R are physically
associated (Tsui et al. 2008). Immunization with TSHR
A-subunit appears to be a requirement for thyroid and orbit
inﬂammation, since immunization with IGF1Ra alone was
inadequate for generating a disease phenotype. On this basis,
we now speculate that the antibody to IGF1Ra following
immunization with TSHR A-subunit may differ from that
induced following immunization with IGF1Ra itself. That
scenario would imply that IGF1Ra antibodies induced by
TSHR A-subunit are pathogenic, either acting alone or in
combination with TSAbs, as suggested by Smith et al. (2008).
Although seemingly clear-cut, our results raise a number of
questions. For instance, what factors drive anti-IGF1Ra
antibody production after challenge with TSHR A-subunit?
Is expansion of anti-IGF1Ra B cell clones driven by TSHR
limited to thyroid and orbit or is it distributed widely? Is it
related to the physical interactions between TSHR and
IGF1R (Tsui et al. 2008). Or, is there immune cross-reactivity
between TSHR A-subunit and IGF1Ra subunit?
Recently, Eckstein et al. have reported trafﬁcking and
accumulation of leukocytes into orbital tissue in female
C57/BL6 mice following immunization with TSHR
A-subunit encoding adenovirus or TSHR plasmid following
depletion of regulatory T cells (Johnson et al. 2010, Ziler et al.
2010). The orbital inﬁltrates comprised F4/80
C macrophages
and CD5
C lymphocytes, conﬁrming the role of autoimmu-
nity against TSHR in orbital inﬂammation. Importantly,
C57/BL6 mice were superior in susceptibility to orbital
inﬁltration to BALB/c mice (Johnson et al. 2010, Ziler et al.
2010). The development of these new models should
facilitate our understanding of the molecular and cellular
basis of GO and its close association with GD. It may also
allow testing of new therapeutic targets in early stages of this
debilitating condition (Banga et al. 2008, Naik et al. 2008).
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